Physicians' Academy for Cardiovascular Education

Practical guidance on NOACs and safety: How to deal with challenging situations in AF

Latest frontiers in anticoagulation therapy (3/4)

15' education - Feb. 20, 2018 - Prof. John Eikelboom, prof. Saskia Middeldorp, Dr. Hanna Pohjantähti-Maaroos

Prof. John Eikelboom discusses the indications for reversal of anticoagulation and results of trials with the available reversal agents.

Video navigation menu

  • Bleeding management principles 01:12
  • Indications for specific reversal 02:15
  • REVERSE-AD trial: dabigatran reversal with idarucizumab 03:40
  • ANNEXA-4 trial: Factor Xa reversal with andexanet alfa 06:28
  • How to reduce bleeding risk? 09:39
  • What is the ratio of bleeding vs surgery in clinical practice for reversal of anticoagulation? 12:57


Show transcript

Educational information

This educational video is part of a series called Latest frontiers in anticoagulation therapy and recorded during an EBAC accredited session held on January 12, 2018

Educational objective:

The overall objective is to provide an expert perspective on appropriate use of NOACs in clinical practice

Educational objectives of the CME session were to:

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.



Prof. John Eikelboom, Associate Professor in the Department of Medicine at McMaster University, Hamilton, Ontario, Canada


Prof. Saskia Middeldorp, internist, professor of Vascular Medicine at the Academic Medical Center Amsterdam, The Netherlands

Dr. Hanna Pohjantähti-Maaroos, Heart Center, Kuopio University Hospital, Finland


Funding to produce this educational video series was provided by an unrestricted educational grant from Boehringer Ingelheim.

View the slides of this presentation Watch other videos from this series and read the Meeting Impression

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: